ELAN Stock Chart & Stats
$380.00
$0.00(0.00%)
At close: 4:00 PM EDT
$380.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$297.51 - $399.50
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$204.41B
Enterprise Value$15.84K
Total Cash (Recent Filing)$530.00M
Total Debt (Recent Filing)$3.92B
Price to Earnings (P/E)―
Beta-0.02
Next Earnings
Nov 06, 2026EPS Estimate
3.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding499,621,830
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)1.72
Price to Sales (P/S)2.38
P/FCF Ratio39.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$569.00Price Target Upside49.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)20.17
Revenue Forecast (FY)$90.97B
Bulls Say, Bears Say
Bulls Say
Organic Revenue GrowthQ2 revenue rose 10% reported and 8% organically, while full-year organic growth guidance increased to 6–7%. The combination of volume and price contribution plus a raised outlook indicates broadening demand and supports more durable revenue momentum across the portfolio.
Innovation Portfolio MomentumInnovation revenue reached $340M in Q2, and the full-year target rose to about $1.25B. Zenrelia’s broad clinic penetration and reorder rate, together with Credelio Quattro’s share gains, show product adoption that can support portfolio growth beyond legacy brands.
Cash Generation And DeleveragingTTM operating cash flow was about $617M and free cash flow about $379M despite negative net income. Positive cash generation provides internal funding for launches and R&D, while first-half net debt reduction and lower leverage improve financial flexibility over the medium term.
Bears Say
Persistent Net LossesDespite improved gross margin and positive EBITDA, TTM net margin remains about -4.9% and ROE about -3.6%. Persistent bottom-line losses mean operating gains are not yet translating into durable shareholder returns and leave less room to absorb execution setbacks.
Meaningful LeverageNet leverage was 3.1x in Q2 and management targets about 3.0x at year-end, while the longer-term target is 2.0–2.5x. Deleveraging is progressing, but the remaining debt burden can constrain capital allocation and make the business more sensitive to operating volatility.
Befrena Supply ConstraintBefrena demand was roughly double expectations, but supply is expected to remain constrained until early 2027 as bioreactor capacity scales and the launch ramps in phases. This could defer revenue capture and limit near-term benefit from a promising new product.
Elanco Animal Health News
ELAN FAQ
What was Elanco Animal Health’s price range in the past 12 months?
Elanco Animal Health lowest stock price was $297.51 and its highest was $399.50 in the past 12 months.
What is Elanco Animal Health’s market cap?
Elanco Animal Health’s market cap is $204.41B.
When is Elanco Animal Health’s upcoming earnings report date?
Elanco Animal Health’s upcoming earnings report date is Nov 06, 2026 which is in 36 days.
How were Elanco Animal Health’s earnings last quarter?
Elanco Animal Health released its earnings results on Aug 05, 2026. The company reported $6.152 earnings per share for the quarter, beating the consensus estimate of $4.868 by $1.285.
Is Elanco Animal Health overvalued?
According to Wall Street analysts Elanco Animal Health’s price is currently Undervalued.
Does Elanco Animal Health pay dividends?
Elanco Animal Health does not currently pay dividends.
What is Elanco Animal Health’s EPS estimate?
Elanco Animal Health’s EPS estimate is 3.71.
How many shares outstanding does Elanco Animal Health have?
Elanco Animal Health has 499,621,830 shares outstanding.
What happened to Elanco Animal Health’s price movement after its last earnings report?
Elanco Animal Health reported an EPS of $6.152 in its last earnings report, beating expectations of $4.868. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Elanco Animal Health?
Currently, no hedge funds are holding shares in MX:ELAN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Elanco Animal Health Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$569.00 (49.74% Upside)
$569.00 (49.74% Upside)
Blogger Sentiment
Neutral
MX:ELAN Sentiment 57%
Sector Average 65%
Sector Average 65%
Insider Transactions
Bought Shares
Worth $9.5M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
11.17%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-1.32%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Elanco Animal Health
Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aquaculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.
ELAN Company Deck
ELAN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was predominantly positive: strong top-line performance (8% organic growth, $1.368B revenue), robust innovation momentum (Zenrelia, Credelio Quattro, AdTab), margin expansion (adjusted gross margin +80 bps, adjusted EBITDA +21%, adjusted EPS +31%), raised full-year guidance, and improving leverage (target ~3.0x year-end). Near-term headwinds include inventory cost pressures, elevated inflation, continued operating expense investments (DTC/R&D) and some regional/timing softness in International Farm Animal. Supply constraints for Befrena and moderating comparisons for some Farm Animal products are acknowledged but framed as manageable. Overall, highlights materially outweigh the limited lowlights.View all MX:ELAN earnings summariesELAN Stock 12 Month Forecast
Average Price Target
$569.00
▲(49.74% Upside)